Last edition
News about "EU Filing for Rare Disease Drug"
Soleno Withdraws EU Filing for Rare Disease Drug Ahead of Neurocrine Takeover
Soleno Therapeutics has withdrawn its European marketing application for Vykat XR, a treatment for hyperphagia associated with Prader-Willi syndrome, ahead of its planned acquisition by Neurocrine Biosciences.
EU Filing For Rare Disease Drug | 09/04/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members